NEU SEES STOCK SURGE

Neuren and Acadia have expanded their global partnership for trofinetide (DAYBUETM), aiming to maximize its value and explore strategic options. The partnership grants Acadia exclusive worldwide rights for trofinetide, with potential payments of up to US$527 million to Neuren, including an upfront payment of US$100 million. Additionally, Neuren's NNZ-2591 shows potential for applications in Rett and Fragile X syndromes globally, with separate sales milestones and royalties. This collaboration strengthens Neuren's position and provides cash flow, with a total of A$226 million as of June 2023. The transaction economics for trofinetide outside North America include upfront payments, sales milestones, and tiered royalties. Trofinetide's economics within North America remains unchanged.

The expanded global partnership between Neuren and Acadia for trofinetide (DAYBUETM) has the potential to lead to an increase in Neuren's stock price for several reasons:

• Maximized Value and Strategic Options: The expansion of the partnership with Acadia demonstrates Neuren's ability to maximize the value of trofinetide. By granting Acadia exclusive worldwide rights for trofinetide, Neuren has solidified a significant collaboration with a well-established partner. This expansion opens up new opportunities and potential strategic options for Neuren, which can be perceived positively by investors and contribute to an increase in the stock price.
• Potential Financial Gains: The partnership includes substantial financial arrangements, with potential payments of up to US$527 million to Neuren, including an upfront payment of US$100 million. This injection of funds and potential future payments provide Neuren with cash flow and financial stability. Investors often view such financial gains positively, as they indicate the potential for increased revenue and profitability, leading to a potential rise in the stock price.
• Strengthened Position and Future Opportunities: The expanded partnership strengthens Neuren's position in the market. By granting Acadia exclusive rights for trofinetide, Neuren aligns itself with a partner that has a strong global presence and resources to maximize the drug's commercial potential. This collaboration increases the likelihood of successful market penetration and future opportunities for trofinetide. Investors may perceive this strengthened position and the potential for future growth as positive signals, potentially driving up the stock price.
• Enhanced Value of NNZ-2591: The partnership expansion also highlights the potential value of Neuren's NNZ-2591, specifically for applications in Rett and Fragile X syndromes globally. This indicates a broader range of opportunities and potential market expansion for Neuren's product portfolio. Investors may view the enhanced value and potential for NNZ-2591 positively, considering it as an additional asset that can contribute to the company's growth prospects and potentially increase the stock price.

It's important to note that stock prices are influenced by a variety of factors and are subject to market dynamics and investor sentiment. While the expanded partnership and its associated benefits can potentially lead to an increase in Neuren's stock price, it's advisable to consider other market factors and conduct thorough research before making investment decisions.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com